Irbesartan reduces progression of renal disease in type 2 diabetes

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1290, 2001-01, pp. : 15-16

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pharmacoeconomic aspects of losartan treatment to delay progression of renal disease in patients with Type 2 diabetes

By Postma Maarten J   Kruidhof Hanneke   Berg Lolkje TW de Jong-van den   Zeeuw Dick de  

Expert Opinion on Pharmacotherapy, Vol. 4, Iss. 9, 2003-09 ,pp. : 1543-1550

Informa Healthcare

Access to resources Recommend Favorite

Mechanism-based disease progression modeling of type 2 diabetes in Goto-Kakizaki rats

By Gao Wei   Bihorel Sébastien   DuBois Debra   Almon Richard   Jusko William  

Journal of Pharmacokinetics and Pharmacodynamics, Vol. 38, Iss. 1, 2011-02 ,pp. : 143-162

Springer Publishing Company

Access to resources Recommend Favorite

The Impact of Losartan on the Lifetime Incidence of End-Stage Renal Disease and Costs in Patients with Type 2 Diabetes and Nephropathy

By Carides George W.  

PharmacoEconomics, Vol. 24, Iss. 6, 2006-01 ,pp. : 549-558

Adis International

Access to resources Recommend Favorite

Soy-based supplement reduces lipid levels in type 2 diabetes

By  

Inpharma, Vol. 1, Iss. 1278, 2001-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite

Liraglutide reduces HbA1c and bodyweight in type 2 diabetes

By  

Inpharma, Vol. 1, Iss. 1504, 2005-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite